leerink partners news

Leerink Partners, Gilead Sciences

Leerink Partners Upgrades Gilead Sciences (GILD)

Fintel reports that on October 21, 2024, Leerink Partners upgraded their outlook for Gilead Sciences (NasdaqGS:GILD) from Market Perform to Outperform. Analyst Price Forecast Suggests 3.16% Downside As of September 24,

Business Insider · 2d

Roivant Sciences (ROIV) Gets a Buy from Leerink Partners

In a report released yesterday, David Risinger from Leerink Partners reiterated a Buy rating on Roivant Sciences (ROIV – Research

bovnews · 14h

Gilead Sciences, Inc. (GILD) Stock Rated Outperform by Leerink Partners

On Tuesday, Gilead Sciences, Inc. (GILD) stock saw a modest uptick, ending the day at $88.16 which represents a slight increase of $1.87 or 2.17% from the prior close of $86.29. The stock opened at $85.

Seeking Alpha · 2d

Gilead upgraded to outperform by Leerink on PrEP outlook

Leerink has upgraded Gilead Sciences (GILD) to outperform, citing the growth outlook for its PrEP medication lenacapavir for the prevention of HIV infection. Read more here.

Business Insider · 2d

Gilead upgraded to Outperform from Market Perform at Leerink

Leerink upgraded Gilead (GILD) to Outperform from Market Perform with a price target of $96, up from $74. The stock has appreciated following

bovnews9h

Trevi Therapeutics Inc (TRVI) Stock Rated Outperform by Leerink Partners

Notable insider trades include GOOD JENNIFER L, President & CEO at Trevi Therapeutics Inc (TRVI), who sold 40277 shares on Sep 05 ’24, at $3.11 each, totaling $0.13 million. On May 29 ’24, SCIASCIA ...

Leerink Partners' Affiliate, MEDACorp, Launches the Center for Pharmacoeconomics to Evaluate the Societal Impact of Healthcare Treatments

Leerink Partners' affiliate, MEDACorp, announced today the launch of a new division, the Center for Pharmacoeconomics (CPE), which will be dedicated to advancing the understanding of the societal ...

Fintel on MSN7d

Leerink Partners Initiates Coverage of Voyager Therapeutics (VYGR) with Outperform Recommendation

Fintel reports that on October 16, 2024, Leerink Partners initiated coverage of Voyager Therapeutics (NasdaqGS:VYGR) with a ...

Voyager Therapeutics (NASDAQ:VYGR) Upgraded at Leerink Partnrs

Leerink Partnrs upgraded shares of Voyager Therapeutics (NASDAQ:VYGR – Free Report) to a strong-buy rating in a research note ...

PE Hub5d

PE firms driving around for parking; Healthcare tech services to come out on top in 2025

Healthcare technology service investments are also expected to be strong in 2025 and in fact, the most active, according to ...

GEN2d

StockWatch: Wave’s RNA Editing Milestone Lifts Korro, ProQR

Two public companies focused on RNA editing therapies, Korro Bio and ProQR, enjoyed impressive stock surges powered by their best-ever one day gains; their share prices lifted by Wave Life Sciences ...

Natera (NASDAQ:NTRA) Given New $150.00 Price Target at Leerink Partners

Natera (NASDAQ:NTRA – Free Report) had its price objective hoisted by Leerink Partners from $140.00 to $150.00 in a report issued on Thursday, Benzinga reports. Leerink Partners currently has an ...

15d

Armentum Partners Makes Key Senior Hire in Andrew Fineberg to Expand Royalty Capabilities

Armentum Partners, the leading investment bank focused exclusively on raising non-dilutive and structured financings for growth stage healthcare and technology companies, is delighted to announce the ...

Cytokinetics’ Strategic Advancements and Upcoming Milestones Signal Strong Growth Potential

Leerink Partners analyst Roanna Ruiz has maintained their bullish stance on CYTK stock, giving a Buy rating on October 17. Roanna Ruiz’s ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results